Literature DB >> 18283647

FXR, a target for different diseases.

Yan-Dong Wang1, Wei-Dong Chen, Wendong Huang.   

Abstract

Great progress has been made in the understanding of the physiological roles of the nuclear receptor farnesoid X receptor (FXR) during the last several years. Roles for FXR were initially identified in the regulation of bile acid, cholesterol, triglyceride, and glucose metabolism. More recently, our group has identified additional functional roles of FXR. Specifically, we have shown that FXR regulates normal liver regeneration and plays a protective role in liver carcinogenesis. These exciting findings suggest that FXR has a broader role than previously thought, and also highlight potential new opportunities for using FXR as a drug target for different diseases. Here we summarize the latest results from studies on FXR response elements, target genes and functions in different diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18283647     DOI: 10.14670/HH-23.621

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  22 in total

1.  Dietary procyanidins enhance transcriptional activity of bile acid-activated FXR in vitro and reduce triglyceridemia in vivo in a FXR-dependent manner.

Authors:  Josep Maria Del Bas; Marie-Louise Ricketts; Montserrat Vaqué; Esther Sala; Helena Quesada; Anna Ardevol; M Josepa Salvadó; Mayte Blay; Lluís Arola; David D Moore; Gerard Pujadas; Juan Fernandez-Larrea; Cinta Bladé
Journal:  Mol Nutr Food Res       Date:  2009-07       Impact factor: 5.914

Review 2.  The glycerophosphoinositols: cellular metabolism and biological functions.

Authors:  Daniela Corda; Pasquale Zizza; Alessia Varone; Beatrice Maria Filippi; Stefania Mariggiò
Journal:  Cell Mol Life Sci       Date:  2009-08-09       Impact factor: 9.261

3.  FXR regulates liver repair after CCl4-induced toxic injury.

Authors:  Zhipeng Meng; Yandong Wang; Lin Wang; Wen Jin; Nian Liu; Hao Pan; Lucy Liu; Lawrence Wagman; Barry M Forman; Wendong Huang
Journal:  Mol Endocrinol       Date:  2010-03-08

4.  Blinded evaluation of farnesoid X receptor (FXR) ligands binding using molecular docking and free energy calculations.

Authors:  Edithe Selwa; Eddy Elisée; Agustin Zavala; Bogdan I Iorga
Journal:  J Comput Aided Mol Des       Date:  2017-09-02       Impact factor: 3.686

5.  Farnesoid X receptor alleviates age-related proliferation defects in regenerating mouse livers by activating forkhead box m1b transcription.

Authors:  Wei-Dong Chen; Yan-Dong Wang; Lisheng Zhang; Steven Shiah; Meihua Wang; Fan Yang; Donna Yu; Barry M Forman; Wendong Huang
Journal:  Hepatology       Date:  2010-03       Impact factor: 17.425

Review 6.  Farnesoid X receptor: a potential therapeutic target in multiple organs.

Authors:  Chao Zhang; Zixuan Wang; Qingqing Feng; Wei-Dong Chen; Yan-Dong Wang
Journal:  Histol Histopathol       Date:  2021-01-04       Impact factor: 2.303

7.  Structural requirements of the human sodium-dependent bile acid transporter (hASBT): role of 3- and 7-OH moieties on binding and translocation of bile acids.

Authors:  Pablo M González; Carlos F Lagos; Weslyn C Ward; James E Polli
Journal:  Mol Pharm       Date:  2013-12-26       Impact factor: 4.939

8.  Farnesoid X receptor antagonizes JNK signaling pathway in liver carcinogenesis by activating SOD3.

Authors:  Yan-Dong Wang; Wei-Dong Chen; Cunbao Li; Cong Guo; Yanyan Li; Hui Qi; Hailing Shen; Jing Kong; Xuecheng Long; Frank Yuan; Xichun Wang; Wendong Huang
Journal:  Mol Endocrinol       Date:  2014-12-12

9.  Bile Acid Receptors and Liver Cancer.

Authors:  Xichun Wang; Xianghui Fu; Carl Van Ness; Zhipeng Meng; Xiaoxiao Ma; Wendong Huang
Journal:  Curr Pathobiol Rep       Date:  2012-12-21

10.  Farnesoid X receptor protects liver cells from apoptosis induced by serum deprivation in vitro and fasting in vivo.

Authors:  Yan-Dong Wang; Fan Yang; Wei-Dong Chen; Xiongfei Huang; Lily Lai; Barry M Forman; Wendong Huang
Journal:  Mol Endocrinol       Date:  2008-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.